%0 Journal Article
%T [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study
%A Bernd Gagel
%A Patrick Reinartz
%A Cengiz Demirel
%A Hans J Kaiser
%A Michael Zimny
%A Marc Piroth
%A Michael Pinkawa
%A Sven Stanzel
%A Branka Asadpour
%A Kurt Hamacher
%A Heinz H Coenen
%A Ulrich Buell
%A Michael J Eble
%J BMC Cancer
%D 2006
%I BioMed Central
%R 10.1186/1471-2407-6-51
%X Eight patients with non-small-cell lung cancer underwent PET scans. Tumour tissue oxygenation was measured with FMISO PET, whereas tumour glucose metabolism was measured with FDG PET. All PET studies were carried out with an ECAT EXACT 922/47£¿ scanner with an axial field of view of 16.2 cm. FMISO PET consisted of one static scan of the relevant region, performed 180 min after intravenous administration of the tracer. The acquisition and reconstruction parameters were as follows: 30 min emission scanning and 4 min transmission scanning with 68-Ge/68-Ga rod sources. The patients were treated with chemotherapy, consisting of 2 cycles of gemcitabine (1200 mg/m2) and vinorelbine (30 mg/m2) followed by concurrent radio- (2.0 Gy/d; total dose 66.0 Gy) and chemotherapy with gemcitabine (300¨C500 mg/m2) every two weeks. FMISO PET and FDG PET were performed in all patients 3 days before and 14 days after finishing chemotherapy.FMISO PET allowed for the qualitative and quantitative definition of hypoxic sub-areas which may correspond to a localization of local recurrences. In addition, changes in FMISO and FDG PET measure the early response to therapy, and in this way, may predict freedom from disease, as well as overall survival.These preliminary results warrant validation in larger trials. If confirmed, several novel treatment strategies may be considered, including the early use of PET to evaluate the effectiveness of the selected therapy.At present, combined modality treatment (chemotherapy followed by surgery or radio-/chemotherapy) for patients with locally advanced non-small-cell lung cancer (NSCLC) is being studied extensively. It is clear, however, that for different reasons, a substantial number of patients had lesser benefits from such intensive treatment. For example, tumour anaemia and tumour hypoxia are considered as multifactorial causes of tumour treatment resistance [4,21]. The causes of tumour hypoxia are multifactorial and include factors related to oxygen de
%U http://www.biomedcentral.com/1471-2407/6/51